IPO: XDx Seeks Funds To Develop Tests For Organ Transplant Rejection
This article was originally published in The Gray Sheet
Executive Summary
Molecular diagnostics firm XDx is planning an initial public stock offering to support the development of blood tests for predicting organ transplant rejection (see chart: "1IPO Details")